1-12 of 12
Douglas Sborov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Shonali Midha, Ashwath Gurumurthi, Patrick Costello, Robert A. Redd, Ciara Louise L. Freeman, Omar Castaneda, Rebecca Gonzalez, Filip Ionescu, Mahmoud Gaballa, Nilesh Kalariya, Jack Khouri, Danai Dima, Mehmet H. Kocoglu, Douglas Sborov, Charlotte B Wagner, Shebli Atrash, Peter M. Voorhees, Hamza Hashmi, James A Davis, Peter A. Forsberg, Joseph P McGuirk, Leyla Shune, Megan Herr, Ran Reshef, Yi Lin, Myo Htut, Thomas Martin, Surbhi Sidana, Doris K. Hansen, Omar Nadeem, Krina K. Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3499.
https://doi.org/10.1182/blood-2023-187565
Published: 2023
Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 4974.
https://doi.org/10.1182/blood-2023-191148
Published: 2023
Journal Articles

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Douglas Peters, Victoria A. Vardell, Gliceida Galarza Fortuna, Sterling Rosqvist, Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Brian McClune, Amandeep Godara, Ghulam Rehman Mohyuddin, Matthew F Covington, Douglas Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 6630.
https://doi.org/10.1182/blood-2023-179287
Published: 2023
Journal Articles

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Douglas Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 6623.
https://doi.org/10.1182/blood-2023-174123
Published: 2023
Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Barry Paul, Jirí Minarík, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Z Usmani, Lin Gu, Michelle Robeson, Michael Murphy, Camille Renard, Christine Chen, Luděk Pour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3383.
https://doi.org/10.1182/blood-2023-186997
Published: 2023
Journal Articles

Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Jiahui Li, Michael Thomas Gambles, Shannuo Li, Jindřich Kopeček, Douglas Sborov, Jiyuan Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3308.
https://doi.org/10.1182/blood-2023-186661
Published: 2023
Journal Articles

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Ana Maria Avila Rodriguez, Danny Hadidi, Craig C. Hofmeister, John Quigley, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, Matias Eugenio Sanchez, Shrihari Kadkol, Douglas Sborov, Damiano Rondelli, Chukwuemeka Uzoka, Karen Sweiss
Journal: Blood
Blood (2023) 142 (Supplement 1): 3395.
https://doi.org/10.1182/blood-2023-190011
Published: 2023
Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 4718.
https://doi.org/10.1182/blood-2023-190746
Published: 2023
Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Charlotte B Wagner, Karen Sweiss, Eric Anto, Rebecca Gonzalez, Omar Alexis Castaneda Puglianini, Ciara Louise L. Freeman, Filip Ionescu, Krina K. Patel, Christopher Ferreri, Mahmoud Gaballa, Leyla Shune, Joseph P McGuirk, Surbhi Sidana, Vanna Hovanky, Jack Khouri, Danai Dima, Hamza Hashmi, James A Davis, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Peter A. Forsberg, Megan Herr, Doris K. Hansen, Douglas Sborov, Mehmet H. Kocoglu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4880.
https://doi.org/10.1182/blood-2023-187440
Published: 2023
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Jonathan L. Kaufman, MD, Jacob P. Laubach, Douglas Sborov, MD MS, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, Jr., MD PhD, Nitya Nathwani, MD, Nina Shah, MD, Yvonne A. Efebera, MD MPH, Sara A. Holstein, MDPhD, Caitlin Costello, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD MSCI, Robert Z. Orlowski, MDPhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, Yana Lutska, PharmD, Padma Bobba, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD, Peter M. Voorhees
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-137109
Published: 2020
Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140078
Published: 2020
Journal Articles

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Francesca Cottini, Douglas Sborov, Yu Kyoung Cho, Misty Lamprecht, Karen Tackett, Junan Li, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister, MD MPH
Journal: Blood
Blood (2016) 128 (22): 5790.
https://doi.org/10.1182/blood.V128.22.5790.5790
Published: 2016